Open AccessSuccessful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report
Author(s) -
Shirin Assar,
Mehran Pournazari,
Parviz Soufivand,
Dena Mohamadzadeh
Publication year - 2022
Publication title -
reumatismo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.294
H-Index - 25
eISSN - 2240-2683
pISSN - 0048-7449
DOI - 10.4081/reumatismo.2021.1437
Subject(s) - medicine , myositis , inflammatory myopathy , prednisolone , muscle biopsy , azathioprine , intravenous immunoglobulin therapy , myopathy , infiltration (hvac) , covid-19 , antibody , muscle weakness , gastroenterology , biopsy , pathology , immunology , disease , infectious disease (medical specialty) , physics , thermodynamics
Neutrophilic myositis (NM) is an inflammatory disorder predominantly characterized by neutrophilic infiltration in the muscles, which is suggested to be an extracutaneous manifestation of neutrophilic dermatosis (ND). NM is a rare disorder which has been occasionally reported in association with hematologic and inflammatory disorders. This case report describes a 45-year-old woman who presented with gradual muscle weakness developed after coronavirus disease 2019 (COVID-19) infection. Electromyography and nerve conduction velocity findings were compatible with inflammatory myopathy and muscle biopsy revealed neutrophilic infiltration. She was successfully treated with intravenous immunoglobulin, prednisolone 1 mg/kg/day and azathioprine 150 mg/day. In conclusion, the COVID-19 infection itself and the drugs used to treat it can cause a number of muscle disorders. Awareness of muscular involvement in COVID-19 infected patients is important for early diagnosis and appropriate treatment.